Intravitreal Injections

From EyeWiki


Intravitreal drug delivery has become the gold standard for treatment of many retinal diseases, including neovascular age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.  The frequency of intravitreal injections has significantly increased since the introduction of anti-vascular endothelial growth factor (VEGF) medications.  The technique involved in properly performing this procedure is important to master in order to optimize patient safety and reduce the risk of complications. 

Common Diseases Treated by Intravitreal Injections

  1. Neovascular AMD
  2. DME/NPDR/PDR (diabetic macular edema/non-proliferative diabetic retinopathy/proliferative diabetic retinopathy)
  3. RVO (retinal vein occlusions)
  4. Endophthalmitis
  5. Uveitis
  6. CME (cystoid macular edema)
  7. CNVM (choroidal neovascular membrane) secondary to multiple retinal diseases

Informed Consent and Risks of Intravitreal Injections

Discuss the indications, risks, benefits, and alternatives with patients.  Obtain informed consent and have the patient's signature on the consent form witnessed. 

The RISKS of intravitreal injections include:

  • Pain / foreign body sensation / epiphora (possibly due to dry eye, corneal abrasion, infection)
  • Bleeding (subconjunctival, vitreous hemorrhage)
  • Retinal tear / detachment
  • Cataract (from inadvertently hitting the lens)
  • Infection (endophthalmitis)
  • Uveitis / retinal vasculitis (higher risk with brolucizumab)
  • Loss of vision (from any of above)
  • Loss of the eye (from a severe infection)
  • Increased intraocular pressure with damage to optic nerve (primarily with steroids but may also occur after higher numbers of anti-VEGF injections)
  • Need for surgery (to address some of the complications above)
  • Stroke/heart attack (with anti-VEGF medications, controversial)
  • Off-label use (for bevacizumab, triamcinolone, other medications)
  • Need for additional injections in future (patients need to understand this)

BENEFITS of intravitreal injections depend on the ocular pathology being treated, but typically include improvement in vision or prevention of worsening vision (in the case of AMD, DR, RVO).  In the case of an infection, the benefit is also direct delivery of the antibiotic/antifungal into the eye close to the nidus of the infection.

ALTERNATIVES to intravitreal injections can include observation, surgery (pars plana vitrectomy), or laser treatment (e.g., laser photocoagulation or photodynamic therapy) depending on the ocular disease.

Common Intravitreal Medications

  • Bevacizumab (Avastin, off-label) 1.25mg/0.05mL (0.675mg/0.03mL if considering using for treatment of Zone I+ ROP in an infant)
  • Ranibizumab (Lucentis) 0.5mg/0.05mL (for neovascular AMD, RVO, myopic CNVM) or 0.3mg/0.05mL (for diabetic retinopathy/DME)
  • Aflibercept (Eylea) 2.0 mg /0.05 mL
  • Brolucizumab (Beovu) 6 mg/0.05 mL
  • Triamcinolone acetonide (Kenalog, off-label) 2mg/0.05mL or 4mg/0.1mL  (Triesence/ Trivaris is alcohol-free preparation that is FDA-approved for intraocular use)
  • Ganciclovir 4mg/0.1mL - administer 2 mg in 0.05 mL (twice weekly for cytomegalovirus retinitis for 14 days for induction)‪
  • Clindamycin 1mg/0.1mL
  • Foscarnet 2.4mg/0.1mL ‬‪- administer 1.2 mg in 0.05 mL
  • Fomivirsen - 330 micrograms/0.05mL
  • Methotrexate - 400 micrograms/0.1mL
  • Vancomycin 1mg/0.1mL
  • Ceftazidime 2.25mg/0.1mL
  • Amikacin 0.4mg/0.1mL
  • Amphotericin B 5 micrograms/0.1mL
  • Voriconazole 50-100 micrograms/0.1mL
  • Dexamethasone 0.4mg/0.1mL

Anesthesia

Topical, subconjunctival, or pledgets are commonly used routes of local anesthesia for in-office intravitreal injections.  The choice of anesthetic depends on physician preference, and is also dictated by how the patient tolerated prior injections.  Retrobulbar block may need to be used for an inflamed eye, such as in the case of endophthalmitis requiring a tap and injection.  However, subconjunctival anesthetic is usually adequate and less painful than a retrobulbar block in an already inflamed eye. An acute inflamed eye is generally a contraindication for intravitreal anti-VEGF injections, especially with brolucizumab.

Several studies have looked at the different anesthetic choices for intravitreal injections.  One randomized controlled trial found that topical anesthesia was effective for most patients.[1] In this study, patients felt the least pain with the actually injection when a subconjunctival anesthetic was given.  However, patients felt more pain when the actual anesthetic was being administered subconjunctivally.  Therefore the collective pain score (anesthesia pain + intravitreal injection pain) was greater for the subconjunctival group compared to the topical group (in which patients had less pain during the administration of the anesthetic, but slightly higher pain score during the actual intravitreal injection).

Topical tetracaine or proparacaine eyedrops can be effective.  In a similar fashion, pledgets soaked with proparacaine or tetracaine can be placed in the fornix and allowed to rest on the globe over the area of planned injection for a short period of time.  Another option is to use a gel type anesthetic, such as lidocaine 2% or 4% jelly or Tetravisc. Some recent reports indicate that the gel may result in trapping of microbes on the ocular surface, so if gel is used it may be best to apply betadine before and after the gel is placed. For subconjunctival anesthesia, typically lidocaine 1% or 2% without epinephrine is effective.

Other points to remember:

  • Subconjunctival anesthesia has a higher risk of causing subconjunctival hemorrhage
  • Allow adequate time for anesthetic to take effect (can be as fast as 1 - 2 minutes for subconj, but would wait longer for topical lidocaine jelly, such as 5 min)
  • If a patient is very nervous or "jumpy" consider a subconjunctival injection so that they injection itself is not felt or minimally felt. Still use topical anesthetics prior to performing the subconjunctival injection to minimize discomfort.
  • If using topical anesthesia (since patients feel the injection more), remind them immediately before the injection that they will feel pressure, so that they do not move with the unanticipated sensation. 

Preparation for Intravitreal Injection

  • Patient should be at least slightly supine with neck well supported
  • Ensure that the headrest is secure and will not unlock during the injection (as patients have a tendency to get nervous and extend their necks and push on the headrest)
  • Close the door and make sure there are no distractions during the injection which could cause the patient to have an ocular saccade
  • Ensure that you have all required instruments before starting, as it is very uncomfortable for patient to wait once Betadine is instilled into the eye
  • Do a surgical "timeout" before the procedure to confirm the correct patient, correct eye, and any allergies.  Preferably the timeout should be done with a technician or a nurse to confirm with the patient the procedure.

Injection Site

  • Superotemporally or inferotemporal for ease of access, though any quadrant can be used.
  • Some retina specialists prefer the superotemporal quadrant, since should a complication such as a retinal detachment occur, it can be treated with a pneumatic retinopexy. 

Asepsis

  • Most important is povidone-iodine 5% solution as it has evidence based data showing risk reduction for endophthalmitis in ocular surgery.
  • Antibiotic use is controversial, and most retina specialists do not pre-treat with antibiotics.[2] Historically, post-procedure antibiotics were given for approximately 3 days (likely for medico-legal reasons).  Several studies have demonstrated that post-injection antibiotics do not reduce the incidence of endophthalmitis.[3][4][5][6]  More importantly, studies show increased antibiotic resistance with the use of post-procedure antibiotics.[7][8]
  • 5% povidone-iodine solution should be placed on the globe and allowed to sit on the eye for at least 30-60 seconds.  One may also use 10% Betadine swabs to gently clean the eye and eyelashes. However, 10% Betadine is associated with more corneal toxicity so care should be taken to avoid getting it in the eye. 
  • Sterile lid speculum with closed blades (to isolate lashes better) or bimanual lid retraction by an assistant
  • Gloves are optional. However, patients may feel more comfortable if the surgeon uses gloves.
  • Do not talk (or cough or sneeze) while preparing or performing the intravitreal injection as studies suggest that there may be a higher risk of oral flora-associated endophthalmitis during intravitreal injections due to talking .[9][10][11]  If you must talk, turn your head away from the surgical field and speak before uncapping the needle.  
  • Consider wearing a mask if there is a need to speak or instruct the patient during the injection as one study suggested that this may yield equivalent outcomes to a no talking policy with potentially a lower incidence of oral flora-associated endophthalmitis.[12] However, if wearing a surgical mask it may be best to face the surgical field as exhalations will exit the mask to the sides and back of the surgical mask.

Injection Technique

Many variations in technique exist, and the following is one example:

  1. Confirm informed consent obtained
  2. Surgical time-out to confirm correct medication and correct eye
  3. Place patient in near supine position; make sure the headrest of the chair is stable
  4. Topical proparacaine (wait 10-15 seconds before placing Betadine)
  5. 10% Betadine swab to inferior cul-de-sac, to allow the Betadine to start working; ask patient to blink multiple times to spread the Betadine
  6. Place 2% lidocaine jelly on the eye, focusing on inferotemporal quadrant.  (Note:  Betadine placed prior to lidocaine jelly to sterilize the globe prior to placing the jelly so as not to have bacteria trapped in the jelly and possibly increase risk of endophthalmitis).
  7. Ask patient to close their eyes, and return in 2-5 minutes.
  8. Apply Betadine swab again to inferotemporal quadrant and inferior cul-de-sac, as well as to eyelashes (do not manipulate much so as not to liberate bacteria from the lashes)
  9. Place sterile closed-blade eyelid speculum (be careful not to cause a corneal abrasion). 
  10. Clean again with Betadine
  11. Mark the location of injection:  3-3.5mm for pseudophakes, 3.5-4.0 mm for phakic patients.  Tip:  Can use the end of a TB syringe (without needle attached) to mark 3.5-4.0 mm.  After marking and causing an indentation with the TB syringe, you can place Betadine again -- the Betadine will slightly pool in the indentation ring and nicely highlight the injection site. 
  12. Have the patient look away from the injection site.  For example, if injecting the right eye in the superotemporal quadrant, ask the patient to look down and to the left. 
  13. Hold syringe in dominant hand, and a cotton-tipped applicator in the non-dominant hand
  14. Do not talk and ask patient not to talk during the injection. Alternatively, wear a mask.  Make sure the needle tip (which is usually a short 30g) is always kept absolutely sterile.
  15. Using your dominant hand, rest your wrist or pinky finger on the patient's face (forehead for superior and cheek for inferior injection sites) for hand stabilization
  16. Insert the needle at the marked site in a smooth and single motion, aiming for the mid-vitreous cavity
  17. Insert the short 30g needle about 1/2 length in (to make sure you are in the vitreous cavity and not in the suprachoroidal space)
  18. Swing over with your non-dominant hand to push down on the plunger in a smooth fashion.  (Note:  some surgeons prefer to inject with one-hand; the author feels that using two hands is more stable).  Do not move the needle while inside the eye so as to not cause traction on the vitreous and potentially cause a retinal tear/detachment.
  19. As you remove the needle, cover the injection site with a cotton-tipped applicator that is in your non-dominant hand
  20. Rinse the Betadine out of the patient's eye
  21. Ensure optic nerve perfusion (patient should be at least light perception).  Paracentesis is usually not required unless a large volume of medication is injected.  Some physicians prefer to check and document the IOP and do not let the patient leave until the IOP has reduced to an acceptable level.  Glaucoma patients may need an anterior chamber paracentesis as their outflow may be compromised. Injecting Kenalog or Triesence 0.1cc causes a rapid and high IOP and it is not uncommon for patients to be temporarily NLP after the injection.  Warn patients about this.  Tip:  One can try to place pressure on the globe (e.g., Lidocaine 4% anesthetic solution on a cotton-tipped applicator at the proposed injection site) to squeeze some aqueous out of the eye and lower the IOP prior to injection and possibly prevent transient NLP vision.  

Post-Injection Care Tips

  • Make sure to wash off Betadine well so the patient does not have irritation/corneal toxicity
  • Reassure patients that they may see floaters which are due to air bubbles or the medication itself (in the case of Kenalog, Triesence, or Dexamethasone implant)
  • Review endophthalmitis and retinal detachment symptoms and precautions
  • Consider a follow-up phone call with patients 3-7 days after the injection
  • A one week in-office follow-up is at the physician's discretion, but is not typically needed.

Bilateral Intravitreal Anti-VEGF Injections

Intravitreal injections of anti-VEGF are traditionally given unilaterally. More recently, there has been an increase in the use of these medications in a bilateral fashion in patients with pathology in both eyes. Common diseases that may need bilateral injections include diabetic macular edema and neovascular AMD, and there is evidence that the rate of bilateral involvement increases with the follow-up and disease duration. [13] A survey of retina specialists in the US in 2011 found that 46% of retina specialists perform bilateral same-day injections. [14] The purpose of bilateral same-day injections is to decrease both physician and patient burden in terms of office visits. In one study, more than 90% of patients strongly preferred bilateral injections to unilateral injections.[15] However, some physicians will avoid bilateral injections for fear of bilateral endophthalmitis. Other local complications should be considered when administering bilateral injections, including inflammation/uveitis, raised intraocular pressure, retinal detachment and subretinal hemorrhages. Separate eyedrops, speculum, needle, and syringe are typically used for each eye to minimize risks.

There have been several large-scale studies of endophthalmitis in bilateral same-day intravitreal anti-VEGF injections. Overall, bilateral injections appear to have a similar safety profile to unilateral injections. The largest study of 101,932 same-day bilateral intravitreal anti-VEGF injections in 5890 patients at a large academic private practice over 5 years found 28 cases of endophthalmitis (0.027% of total injections) with no cases of bilateral endophthalmitis.[16] Other similar studies have found the incidence of endophthalmitis from 0-0.01% to 0.065%.[17] [18] [19][20][21]

Follow up

  • Depends on the disease being treated and duration of treatment. Early on, patients may require monthly injections and follow-up. Later in the course as the disease is stabilized, some advocate extending the interval between injections permitting less frequent injections and follow-up visits.

Similar safety and efficacy of intravitreal bevacizumab compared to ranibizumab

Numerous trials (CATT[22], IVAN[23], GEFAL[24], MANTA[25], LUCAS[26]) conducted worldwide have shown intravitreal bevacizumab to be non-inferior to ranibizumab in terms of efficacy and safety in AMD. Bevacizumab has the advantage of significantly reducing the cost of therapy. However, intravitreal bavacizumab injection has not been approved by the Food and Drug Administration (FDA) and the use in the eye is hence 'off label'. All patients need to be clearly informed of this when obtaining written consent for intravitreal bevacizumab injection.

Additional Resources

References

  1. Blaha GR, Tilton EP, Barouch FC, Marx JL.Randomized trial of anesthetic methods for intravitreal injections. Retina. 2011 Mar;31(3):535-9.
  2. Uhr JH, Xu D, Rahimy E, Hsu J. Current Practice Preferences and Safety Protocols for Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. Ophthalmol Retina. 2019 Aug;3(8):649-655. doi: 10.1016/j.oret.2019.03.013. Epub 2019 Mar 22. PMID: 31068264.
  3. Storey P, Dollin M, Pitcher J, Reddy S, Vojtko J, Vander J, Hsu J, Garg SJ; Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014 Jan;121(1):283-289. doi: 10.1016/j.ophtha.2013.08.037. Epub 2013 Oct 18. PMID: 24144453.
  4. Rumya R. Rao, Golnaz Javey, Philip J. Rosenfeld, William J. Feue.  Elimination of Post-Injection Topical Antibiotics after Intravitreal Injections.  ARVO May, 2011
  5. Reibaldi M, Pulvirenti A, Avitabile T, Bonfiglio V, Russo A, Mariotti C, Bucolo C, Mastropasqua R, Parisi G, Longo A. POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. Retina. 2018 Jan;38(1):1-11. doi: 10.1097/IAE.0000000000001583. PMID: 28267115.
  6. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012 Aug;119(8):1609-14. doi: 10.1016/j.ophtha.2012.02.014. Epub 2012 Apr 4. PMID: 22480743.
  7. 3. Kim SJ, Toma HS.  Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.Ophthalmology. 2011 Jul;118(7):1358-63. Epub 2011 Mar 21.
  8. Storey P, Dollin M, Rayess N, Pitcher J, Reddy S, Vander J, Hsu J, Garg S; Post-Injection Endophthalmitis Study Team. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):235-42. doi: 10.1007/s00417-015-3035-x. Epub 2015 May 5. PMID: 25940556.
  9. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011 Dec;129(12):1551-4. doi: 10.1001/archophthalmol.2011.227. Epub 2011 Aug 8. PMID: 21825179.
  10. Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina. 2011 Sep;31(8):1525-33. doi: 10.1097/IAE.0b013e318221594a. Erratum in: Retina. 2011 Nov;31(10):2139. PMID: 21878800.
  11. Garg SJ, Dollin M, Storey P, Pitcher JD 3rd, Fang-Yen NH, Vander J, Hsu J; Post-Injection Endophthalmitis Study Team. MICROBIAL SPECTRUM AND OUTCOMES OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION VERSUS PARS PLANA VITRECTOMY. Retina. 2016 Feb;36(2):351-9. doi: 10.1097/IAE.0000000000000694. PMID: 26200514.
  12. Patel SN, Hsu J, Sivalingam MD, Chiang A, Kaiser RS, Mehta S, Park CH, Regillo CD, Sivalingam A, Vander JF, Ho AC, Garg SJ; Wills Post-Injection Endophthalmitis (PIE) Study Group. The Impact of Physician Face Mask Use on Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2020 Sep 2;222:194-201. doi: 10.1016/j.ajo.2020.08.013. Epub ahead of print. PMID: 32888902; PMCID: PMC7462768.
  13. Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol. 2016;16:142. Published 2016 Aug 9. doi:10.1186/s12886-016-0317-y
  14. Survey of intravitreal injection techniques among retinal specialists in the United States Am J Ophthalmol, 151 (2) (2011), pp. 329-332).
  15. Mahajan VB, Elkins KA, Russell SR, et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina. 2011;31(1):31‐35. doi:10.1097/IAE.0b013e3181ed8c80
  16. Borkar DS, Obeid A, Su DC, et al. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2018;194:1‐6. doi:10.1016/j.ajo.2018.06.022
  17. Juncal VR, Francisconi CLM, Altomare F, et al. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. Ophthalmologica. 2019;242(1):1‐7. doi:10.1159/000499115
  18. Ruão M, Andreu-Fenoll M, Dolz-Marco R, Gallego-Pinazo R. Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents. Clin Ophthalmol. 2017;11:299‐302. Published 2017 Feb 1. doi:10.2147/OPTH.S124282
  19. Chao DL, Gregori NZ, Khandji J, Goldhardt R. Safety of bilateral intravitreal injections delivered in a teaching institution. Expert Opin Drug Deliv. 2014;11(7):991‐993. doi:10.1517/17425247.2014.909806
  20. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009;29(9):1213‐1217. doi:10.1097/IAE.0b013e3181b32d27
  21. Woo SJ, Han JM, Ahn J, et al. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina. 2012;32(4):667‐671. doi:10.1097/IAE.0b013e31822c296b
  22. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1. PMID: 22555112; PMCID: PMC3389193.
  23. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11. Erratum in: Ophthalmology. 2012 Aug;119(8):1508. Erratum in: Ophthalmology. 2013 Sep;120(9):1719. PMID: 22578446.
  24. Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2. PMID: 23916488.
  25. Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391. Epub 2013 Jan 3. PMID: 23292928.
  26. Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13. PMID: 25227499.
  1. Intravitreal Injections, Focal Points, Volume XXVII, Number 8, September 2009.